量子生物(300149.SZ)2019年淨利跌13.75%至1.39億元
格隆匯4月23日丨量子生物(300149.SZ)披露2019年年度報告,報告期實現營業收入13.28億元,同比增長33.19%;歸屬於上市公司股東的淨利潤1.39億元,同比減少13.75%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.19億元,同比減少20.53%;基本每股收益0.28元。
報告期內,公司實現營業總收入同比增長33.19%,主要是該期合併上海睿智1-12月報表,而上年同期只合並了上海睿智6-12月報表;其中:1、醫藥研發服務與生產外包業務報告期內實現營業收入10.98億元,較上年同比口徑同期增長2.35%;2、微生態營養與醫療業務報告期內實現營業收入2.32億元,較上年同期下降22.53%。
歸屬於公司普通股股東的淨利潤較上年同期下降13.75%,主要是上海睿智產能擴張及研發服務能力建設階段性投入增加、因收購上海睿智的併購貸款利息計提期間較上年同期增加了6個月導致財務費用增加、微生態營養業務營收下降等原因導致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.